Intensity Therapeutics Inc. (NASDAQ:INTS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $7.00.
Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Monday, October 19th. Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Finally, HC Wainwright increased their price objective on Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th.
Get Our Latest Stock Analysis on INTS
Intensity Therapeutics Stock Performance
Intensity Therapeutics stock opened at $2.64 on Thursday. The firm has a fifty day simple moving average of $3.46 and a two-hundred day simple moving average of $4.84. The company has a quick ratio of 3.68, a current ratio of 3.68 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a twelve month low of $2.53 and a twelve month high of $15.00. The company has a market capitalization of $8.71 million, a PE ratio of -0.84 and a beta of 2.78.
Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.10). Research analysts expect that Intensity Therapeutics will post -4.32 EPS for the current year.
About Intensity Therapeutics
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for solid tumors. Its approach centers on delivering cancer-killing agents directly into tumors, with the goal of treating the tumor while also stimulating an immune response. The company’s lead investigational product, INT230-6, combines the chemotherapy agents cisplatin and vinblastine sulfate with a proprietary molecule intended to help the drugs spread through tumor tissue and enter cancer cells. Intensity has evaluated INT230-6 in clinical studies as a treatment for solid tumors.
Featured Stories
- Five stocks we like better than Intensity Therapeutics
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
